Keith Wilson, MD, VUMC’s principal investigator and director of the Vanderbilt Center for Mucosal Inflammation and Cancer, said the effort will help bridge the bench-to-bedside gap between discovery science and improving treatment options for patients. “This is a good beginning,” he said, “the tip of the iceberg.”